Logo image of DWTX

DOGWOOD THERAPEUTICS INC (DWTX) Stock Fundamental Analysis

NASDAQ:DWTX - Nasdaq - US92829J2033 - Common Stock

3.15  +1.28 (+68.45%)

Premarket: 2.74 -0.41 (-13.02%)

Fundamental Rating

2

Overall DWTX gets a fundamental rating of 2 out of 10. We evaluated DWTX against 572 industry peers in the Biotechnology industry. While DWTX seems to be doing ok healthwise, there are quite some concerns on its profitability. DWTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DWTX had negative earnings in the past year.
In the past year DWTX has reported a negative cash flow from operations.
In the past 5 years DWTX always reported negative net income.
DWTX had a negative operating cash flow in each of the past 5 years.
DWTX Yearly Net Income VS EBIT VS OCF VS FCFDWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

DWTX has a Return On Assets of -145.66%. This is amonst the worse of the industry: DWTX underperforms 84.25% of its industry peers.
DWTX has a Return On Equity of -168.89%. This is in the lower half of the industry: DWTX underperforms 66.55% of its industry peers.
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROIC N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DWTX Yearly ROA, ROE, ROICDWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DWTX Yearly Profit, Operating, Gross MarginsDWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

DWTX has more shares outstanding than it did 1 year ago.
DWTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DWTX Yearly Shares OutstandingDWTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 5M 10M 15M
DWTX Yearly Total Debt VS Total AssetsDWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

DWTX has an Altman-Z score of -23.45. This is a bad value and indicates that DWTX is not financially healthy and even has some risk of bankruptcy.
DWTX's Altman-Z score of -23.45 is on the low side compared to the rest of the industry. DWTX is outperformed by 88.67% of its industry peers.
DWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.45
ROIC/WACCN/A
WACCN/A
DWTX Yearly LT Debt VS Equity VS FCFDWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

DWTX has a Current Ratio of 7.27. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
DWTX's Current ratio of 7.27 is fine compared to the rest of the industry. DWTX outperforms 68.32% of its industry peers.
A Quick Ratio of 7.27 indicates that DWTX has no problem at all paying its short term obligations.
The Quick ratio of DWTX (7.27) is better than 68.50% of its industry peers.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 7.27
DWTX Yearly Current Assets VS Current LiabilitesDWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

DWTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
EPS 1Y (TTM)20.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.31%
EPS Next 2Y-4.09%
EPS Next 3Y12.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DWTX Yearly Revenue VS EstimatesDWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
DWTX Yearly EPS VS EstimatesDWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DWTX Price Earnings VS Forward Price EarningsDWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DWTX Per share dataDWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

DWTX's earnings are expected to grow with 12.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.09%
EPS Next 3Y12.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DOGWOOD THERAPEUTICS INC

NASDAQ:DWTX (1/21/2025, 8:00:02 PM)

Premarket: 2.74 -0.41 (-13.02%)

3.15

+1.28 (+68.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners3.6%
Inst Owner ChangeN/A
Ins Owners6.74%
Ins Owner Change0%
Market Cap4.19M
Analysts80
Price TargetN/A
Short Float %1.27%
Short Ratio0.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.49%
Min EPS beat(2)-71.57%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)5.94%
Min EPS beat(4)-71.57%
Max EPS beat(4)38.08%
EPS beat(8)6
Avg EPS beat(8)18.36%
EPS beat(12)10
Avg EPS beat(12)18.83%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-6.55
EYN/A
EPS(NY)-7.58
Fwd EYN/A
FCF(TTM)-3.14
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0
BVpS2.36
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.66%
ROE -168.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-124.88%
ROA(5y)-235.88%
ROE(3y)-138.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 7.27
Altman-Z -23.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.67%
EPS Next Y6.31%
EPS Next 2Y-4.09%
EPS Next 3Y12.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.44%
OCF growth 3YN/A
OCF growth 5YN/A